Cipla to exceed FY25 guidance, sees minimal impact from PEPFAR funding freeze

Share it

Cipla is confident of surpassing its FY25 guidance, with supply challenges for Lanreotide expected to ease by Q1FY26. The trade business has stabilised, and a key drug launch is planned for H2 FY26.

Leave a Comment

Your email address will not be published. Required fields are marked *